Zobrazeno 1 - 2
of 2
pro vyhledávání: '"35"'
Autor:
Geoffrey I. Shapiro, CL Arteaga, David B. Solit, David M. Hyman, Anna Butturini, IA Mayer, Sherene Loi, Feng Xu, J. Baselga, Sarina Anne Piha-Paul, Cristina Saura, Alshad S. Lalani, Funda Meric-Bernstam, Richard E. Cutler, Richard A. Bryce
Publikováno v:
Cancer Research. 77:PD2-08
Background: Somatic mutations in ERBB2 are a new class of oncogenic drivers in HER2–non amplified MBC. Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits the growth of ERBB2-mutant breast tumors in preclinical models and h
Autor:
MJ Ellis, A Tavaarwerk, MP Goetz, Jeremy Hoog, Cynthia X. Ma, Charles Erlichman, Tina J. Hieken, Julie A. Margenthaler, Timothy J. Moynihan, Mark E. Burkard, Michael Naughton, Foluso O. Ademuyiwa, Charles L. Loprinzi, L Doyle, VJ Suman, Tufia C. Haddad, S Sanati, Hussam Al-Kateb, Kiran Vij, Donald W. Northfelt, Richard Gray, Zhanfang Guo, J Han, Rebecca Aft, Lee G. Wilke, Elaine R. Mardis
Publikováno v:
Cancer Research. 76:P5-13
Background Activating mutations in PIK3CA occur in approximately 40% ER+BC. MK-2206 (M), a pan-AKT inhibitor, induced apoptosis of ER+ BC under estrogen deprivation in preclinical studies. We conducted this neoadjuvant trial to determine the patholog